Chris Boshoff: Pfizer announced a 5-year update from our Phase 3 study for patients with ALK+ advanced NSCLC

Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared on LinkedIn:

“Today at ASCO24, I am thrilled to share that Pfizer announced a 5-year update from our Phase 3 study, showing unprecedented results for patients with ALK+ advanced NSCLC. Read more here.

ALK+ advanced NSCLC is typically aggressive and often impacts younger people in the prime of their lives. I have had the privilege to see how our precision medicines have had a positive impact for patients since the discovery of the first ALK inhibitor more than 10 years ago.

The results being presented today, show that a majority of patients are living beyond five years without disease progression, representing Pfizer’s commitment to making significant progress in the treatment of this disease. .

Thank you to all the Pfizer colleagues, investigators, patients and their families who had a role in the trial and contributed to this milestone. It is a great honor to see the culmination of this work shared with the community.”

Source: Chris Boshoff/LinkedIn